Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung15: datopotamab deruxtecan with or without osimertinib versus platinum-pemetrexed chemotherapy after osimertinib in EGFR-mutated non-small cell lung cancer
2024-511362-37-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of darunavir + cobicistat and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
darunavir + cobicistatosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511362-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511362-37-00.